ClinicalTrials.gg
RecruitingNCT06269770Updated May 14, 2024

Tapentadol vs Tramadol in Total Knee Arthroplasty

A Phase 4 interventional study of Tapentadol and Tramadol in Total Knee Replacement, Post-operative Pain and Chronic Pain, sponsored by University of Thessaly. Recruiting at 1 site in Greece. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by University of Thessaly · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Registered 9 months after the study started (first participant enrolled May 2023, registered Feb 2024).
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing tapentadol in Pain, Postoperative — 1 open to participants now, 1 under way, none of them phase 3. Tapentadol · Pain, Postoperative.

Planned enrollment
6th of 12
96 · median 91
Started
2023
the only one that year
Phase 4
2 of 12
1 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
University of Thessaly

Among the 12 studies testing tapentadol in Pain, Postoperative, this one is the 6th largest by planned enrollment, is the only one that started in 2023, is one of 2 in phase 4, and was the 11th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

1 of the 12 studies testing tapentadol in Pain, Postoperative is open now, in 1 country.

By country, each count listing its studies:

About tapentadol

Tapentadol: first FDA approval 2008 (NUCYNTA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing tapentadol in Pain, Postoperative, or all of them as a file.
02

Study summary

Compare the effectiveness of tapentadol and tramadol as part of a multimodal analgesia treatment for Total Knee Replacement (TKR).

Read the detailed description

As the population ages and becomes more active, the demand for TKR surgery is expected to increase. However, the treatment of TKR pain remains a challenge.

Postoperative pain is associated with longer hospital stays, lower satisfaction, increased opioid consumption, and transition to chronic pain. In TKR, the risk of chronic pain can be as high as 20%.

A suggested method of anesthesia and pain relief is the use of spinal anesthesia along with multimodal analgesia that includes an adductor canal block.

In our hospital, the multimodal analgesia protocol consists of intraoperative sedation with dexmedetomidine, a low dose of ketamine, paracetamol, NSAIDs, and magnesium. Dexamethasone and droperidol are preferred as antiemetics as they can improve the analgesic outcome.

To minimize the use of opioids, the administration of tramadol used to be the standard of care. Tapentadol is an opioid that can be equally effective in the treatment of postoperative pain and reduces the incidence of chronic pain after TKR.

03

Conditions studied

  • Total Knee Replacement
  • Post-operative Pain
  • Chronic Pain

Keywords

  • total knee replacement
  • post-operative pain
  • tramadol
  • tapentadol
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients for elective TKR
  • I - III

Exclusion criteria

Exclusion Criteria:

  • Patient refusal
  • Cognitive disfunction
  • Severe psychiatric disease
  • Under medication with MAO inhibitors, tricyclic antidepressants, serotonin reuptake inhibitors
  • Not speaking Greek
  • Known allergy to the study drugs
  • for any of the study drugs
  • Chronic renal failure ( \< 50 ml/h)
  • Liver failure
  • Known regular use or misuse of opioids
  • Pregnant women
  • Patients undergoing general anesthesia
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Active comparator
    Tramadol

    Tramadol will be administered in a multimodal analgesic approach to manage postoperative pain.

    Drug: Tramadol

  • Active comparator
    Tapentadol

    Tapentadol will be administered in a multimodal analgesic approach to manage postoperative pain.

    Drug: Tapentadol

Interventions

  • Add tapentadol, for effective pain management in a multimodal setting during TKR.

  • Add tramadol, for effective pain management in a multimodal setting during TKR.

06

What researchers measure

Primary outcomes

  1. Post-operative pain

    Visual Analogue Scale (VAS) score measures 0 to 10 (0=no pain, 10=the worst pain)

    Time frame: 6 hours after surgery

  2. Post-operative pain

    Visual Analogue Scale (VAS) score measures 0 to 10 (0=no pain, 10=the worst pain)

    Time frame: 12 hours after surgery

  3. Post-operative pain

    Visual Analogue Scale (VAS) score measures 0 to 10 (0=no pain, 10=the worst pain)

    Time frame: 1st postoperative day

  4. Post-operative pain

    Visual Analogue Scale (VAS) score measures 0 to 10 (0=no pain, 10=the worst pain)

    Time frame: 2nd postoperative day

  5. Post-operative pain

    Visual Analogue Scale (VAS) score measures 0 to 10 (0=no pain, 10=the worst pain)

    Time frame: 3rd postoperative day

Secondary outcomes

  1. Post-operative pain

    Visual Analogue Scale (VAS) score measures 0 to 10 (0=no pain, 10=the worst pain)

    Time frame: 3 weeks after surgery

  2. Post-operative pain

    Visual Analogue Scale (VAS) score measures 0 to 10 (0=no pain, 10=the worst pain)

    Time frame: 6 weeks after surgery

  3. Post-operative pain

    Visual Analogue Scale (VAS) score measures 0 to 10 (0=no pain, 10=the worst pain)

    Time frame: 6 months after surgery

  4. Neuropathic pain

    PainDETECT (0-35)

    Time frame: 6 months after surgery

  5. Quality of life postoperatively

    Patient Quality 15 (0-150)

    Time frame: 6 months after surgery

  6. Patient Satisfaction

    5-point Likert scale (0-5) \[5 representing higher satisfaction\]

    Time frame: 5 days after surgery at Discharge

  7. Depression

    Patient Health Questionnaire 9 (PHQ9) (0-27) \[The higher the score, more severe the depression\]

    Time frame: 5 days after surgery at Discharge

  8. Function

    Oxford Knee Score (OKS) (0-48)

    Time frame: 6 weeks after surgery

  9. Outcome

    Knee Injury and Osteoarthritis Outcome Score (KOOS) (0-100)

    Time frame: 6 weeks after surgery

  10. Arthritis impact

    ARTHRITIS IMPACT MEASUREMENT SCALES 2 Short Form (AIMS2-SF) (5Likert scale

    Time frame: 6 weeks after surgery

  11. Health Status

    5 level EuroQol 5 Dimensions 5 level Score (EQ-5D-5L) (0-100) \[The higher the score, the worse the health status\]

    Time frame: 6 weeks after surgery

  12. Pain severity

    Western Ontario and McMaster Universities Osteoarthritis (WOMAC) (0-96) \[The higher the score the higher the disability due to osteoarthritis\]

    Time frame: 6 weeks after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Baratta JL, Gandhi K, Viscusi ER. Perioperative pain management for total knee arthroplasty. J Surg Orthop Adv. 2014 Spring;23(1):22-36. doi: 10.3113/jsoa.2014.0022. PubMed 24641894 ↗
  • Roulet L, Rollason V, Desmeules J, Piguet V. Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients. Drugs. 2021 Jul;81(11):1257-1272. doi: 10.1007/s40265-021-01515-z. Epub 2021 Jul 1. PubMed 34196947 ↗
  • Rian T, Skogvoll E, Hofstad J, Hovik L, Winther SB, Husby VS, Klaksvik J, Egeberg T, Sand K, Klepstad P, Wik TS. Tapentadol vs oxycodone for postoperative pain treatment the first 7 days after total knee arthroplasty: a randomized clinical trial. Pain. 2021 Feb 1;162(2):396-404. doi: 10.1097/j.pain.0000000000002026. PubMed 32773594 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for May 2025, 24 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 24 months is above that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2024
First posted
Feb 21, 2024
StartActual
May 1, 2023
Primary completionEst.
May 1, 2025
CompletionEst.
Jun 1, 2025
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06269770
Responsible party
Elena Arnaoutoglou (Professor in Anesthesiology, University of Thessaly) — Principal investigator
First posted
Feb 21, 2024
Start date
May 1, 2023
Primary completion
May 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
May 14, 2024

Study contacts

Eleni Arnaoutoglou, MD, PhD
Contact
earnaout@gmail.com
00302413502952
Metaxia Bareka, MD, PhD
Contact
barekametaxia@hotmail.com
+306947845083
Eleni Arnaoutolglou, MD, PhD
study chair · Department of Anesthesiology, Faculty of Medicine, School of Health Sciences, University of Thessaly
Metaxia Bareka, MD, PhD
principal investigator · Department of Anesthesiology, Faculty of Medicine, School of Health Sciences, University of Thessaly

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tapentadol · Tramadol

Start the discussion